Clinical Trials Sponsored by HRA Pharma

Total 8694 results

HRA Pharma

Completed

Safety and Efficacy of CDB-2914 in Comparison to Levonorgestrel for Emergency Contraception

Contraception

United States, Ireland, United Kingdom
HRA Pharma

Completed

Safety and Efficacy of CDB-2914 for Emergency Contraception

Emergency Contraception

United States
HRA Pharma

Terminated

Prospective, Open-Label, Multicenter, International Study of Mifepristone for Symptomatic Treatment of Cushing's Syndrome Caused by Ectopic Adrenal Corticotrophin Hormone (ACTH) Secretion

Cushing's Syndrome

United States, Netherlands, France, Italy, Germany
HRA Pharma

Completed

Adherence With Continuous-dose Oral Contraceptive: Evaluation of Self-Selection and Use (ACCESS)

Contraception

United States
HRA Pharma

Terminated

A Study of Oral Contraception Under Simulated OTC Conditions (OPTION)

Contraception

United States
HRA Pharma

Completed

Effects of Metyrapone in Patients With Endogenous Cushing's Syndrome (PROMPT)

Cushing's Syndrome

Germany, Belgium, Italy, Hungary, Poland, Romania, Spain, Turkey
HRA Pharma

Completed

Clinical Follow-up and Outcomes of Pregnancies Exposed to Ella (ellipseII)

Emergency Contraception

United States
HRA Pharma

Completed

Safety, Tolerability, and Efficacy of ellaOne® (Ulipristal Acetate) for Emergency Contraception in Postmenarcheal Adolescent Girls and Women

Contraception

United States, Sweden, United Kingdom
HRA Pharma

Completed

Comparison of CDB-2914 Versus Placebo in the Prevention of Follicular Rupture Post-luteinizing Hormone (LH) Surge

Contraception

Chile, Dominican Republic
HRA Pharma

Completed

Low Dose Continuous Administration of the Progesterone Receptor Modulator VA2914

Contraception | Gynecologic Diseases

France, Belgium
HRA Pharma

Recruiting

Observational Registry on Patients With Endogenous CS to Document Safety and Effectiveness of Ketoconazole. (KetoPASS)

Cushing Syndrome

Sweden, France, Croatia, Spain
HRA Pharma

Completed

A Study of Use of Ella®, an Emergency Contraceptive, Under Simulated OTC Conditions (LIBRella)

Emergency Contraception

United States
HRA Pharma

Completed

Assessment of Effects on Ovarian Activity of a Combined Oral Contraceptive Pill When Preceded by the Intake of ellaOne® or Placebo.

Emergency Contraception

Sweden, Netherlands, United Kingdom
HRA Pharma
Health Decisions

Completed

Effect of Norgestrel 75 mcg on Cervical Mucus and Ovarian Activity During Perfect Use, After One Delayed Intake and After a Missed Pill

Contraception

United States
Istituto Auxologico Italiano
HRA Pharma

Recruiting

Effects of Metyrapone in Patients With Hypercortisolism (CEM)

Hypercortisolism

Italy
Sheffield Teaching Hospitals NHS Foundation Trust
HRA Pharma

Completed

Glucocorticoid Receptor Antagonism in Subclinical Cushings

Subclinical Cushing's

United Kingdom
Okyo Pharma Ltd
ORA, Inc.

Completed

The Study Evaluating the Efficacy and Safety of OK-101 in Subjects With Dry Eye Disease

Dry Eye Disease

United States
Enyo Pharma
PRA Health Sciences

Completed

EYP001a Food Effect Study in Subjects With Chronic Hepatitis B Virus (HBV) Infection

Hepatitis B, Chronic

Netherlands
Enyo Pharma
PRA Health Sciences

Completed

Study Evaluating Safety, Tolerability and Pharmacokinetics of EYP001a in Healthy Male Subjects

Healthy
ORA, Inc.
Topivert Pharma Ltd

Completed

Safety and Efficacy of TOP1630 for Dry Eye Syndrome

Dry Eye Syndrome

United States
Herantis Pharma Plc.
ORA, Inc.

Completed

Phase 2 Study With Cis-UCA Ophthalmic Solutions in Subjects With Dry Eye

Dry Eye Syndrome

United States
Ra Pharmaceuticals

Completed

Phase 2 Safety and Efficacy Study of Zilucoplan (RA101495) to Treat PNH Patients

Paroxysmal Nocturnal Hemoglobinuria (PNH)

United Kingdom, Australia, Canada, Denmark, Finland, Germany, Hungary, New Zealand
Ra Pharmaceuticals

Completed

Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia Gravis

Generalized Myasthenia Gravis

United States, Canada
Ra Pharmaceuticals

Terminated

Safety and Efficacy Study of Zilucoplan in Subjects With Immune-Mediated Necrotizing Myopathy

Immune Mediated Necrotizing Myopathy

United States, Netherlands, France, United Kingdom
Ra Pharmaceuticals

Completed

Phase 2 Safety and Efficacy Study of Zilucoplan (RA101495) to Treat PNH Patients Who Have an Inadequate Response to Eculizumab

Paroxysmal Nocturnal Hemoglobinuria (PNH)

United States
UCB Celltech
PRA Health Sciences

Terminated

UCB Proof of Concept Study in Patients With Primary Sjögren's Syndrome

Primary Sjögren's Syndrome

France, Italy, Spain, Sweden, United Kingdom
UCB Celltech
PRA Health Sciences

Completed

Multiple Dose Study of UCB4940 as add-on to Certolizumab Pegol in Subjects With Rheumatoid Arthritis

Rheumatoid Arthritis

Czechia, Hungary, Moldova, Republic of, Poland, Russian Federation, Slovakia, United Kingdom
UCB Pharma
Yale University; PRA Health Sciences

Completed

A Brain Imaging Study With Positron Emission Tomography and the Radiotracer [11C]UCB-J to Estimate How Fast Brivaracetam and Levetiracetam Enter the Brain in Healthy Volunteers

Healthy Volunteers

United States
Orion Corporation, Orion Pharma
PRA Health Sciences

Terminated

Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of ODM-108: in Healthy Male Volunteers (FIMTRIP)

Healthy

Netherlands
Ra Pharmaceuticals, Inc.

Terminated

Extension Study of RA101495 for Patients With PNH Who Have Completed a Zilucoplan (RA101495) Clinical Study

Paroxysmal Nocturnal Hemoglobinuria (PNH)

United States, Australia, Canada, Finland, Germany, Hungary, New Zealand, United Kingdom
Ra Pharmaceuticals, Inc.

Active, not recruiting

Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis (RAISE-XT)

Generalized Myasthenia Gravis

United States, Canada, France, Germany, Italy, Japan, Norway, Poland, Spain, United Kingdom
Ra Pharmaceuticals, Inc.

Completed

Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis (RAISE)

Myasthenia Gravis, Generalized

United States, Canada, France, Germany, Italy, Japan, Norway, Poland, Spain, United Kingdom
UCB Biopharma S.P.R.L.
PRA Health Sciences

Completed

Evaluating the Effectiveness of Neupro® (Rotigotine) and L-dopa Combination Therapy in Patients With Parkinson's Disease (NEUPART)

Idiopathic Parkinson's Disease

Germany, France, Italy, Spain, United Kingdom
UCB Biopharma S.P.R.L.
PRA Health Sciences

Completed

A Study of UCB0942 in Adult Patients With Highly Drug-resistant Focal Epilepsy

Highly Drug-resistant Focal Epilepsy

Belgium, Bulgaria, Germany, Hungary, Netherlands, Spain
UCB Biopharma S.P.R.L.
PRA Health Sciences

Completed

Study to Evaluate Properties of Radiprodil Given in Oral Solution to Healthy Volunteers

Healthy Volunteers

Netherlands
BHR Pharma, LLC
Syneos Health; PRA Health Sciences

Completed

Efficacy and Safety Study of Intravenous Progesterone in Patients With Severe Traumatic Brain Injury (SyNAPSe)

Brain Injuries

Spain, United States, United Kingdom, Austria, Netherlands, Taiwan, Belgium, Singapore, Israel, Germany, Finland, China, Thailand, Malaysia, France, Hungary, Italy, Czech Republic, Argentina, Romania, Russian Federation
Faes Farma, S.A.
ORA, Inc.

Completed

A Study Evaluating Bilastine Ophthalmic Solution 0.6% in the Conjunctival Allergen Challenge (Ora-CAC®) Model.

Allergic Conjunctivitis

United States
UCB BIOSCIENCES GmbH
PRA Health Sciences

Completed

Pediatric Arthritis Study of Certolizumab Pegol (PASCAL)

Polyarticular-course Juvenile Idiopathic Arthritis (JIA)

United States, Argentina, Brazil, Canada, Chile, Mexico, Russian Federation
UCB BIOSCIENCES GmbH
PRA Health Sciences

Completed

Study of Lacosamide as an Adjunctive Drug Treatment for Epilepsy in Patients With Brain Tumors (VIBES)

Brain Tumor Related Epilepsy (BTRE)

Italy, France, Germany, Netherlands, Spain, United Kingdom
UCB BIOSCIENCES, Inc.
PRA Health Sciences

Terminated

Efficacy Evaluation of Intravenous Brivaracetam and Phenytoin in Subjects With Nonconvulsive Electrographic Seizures

Nonconvulsive Electrographic Seizures

United States
Faes Farma, S.A.
ORA, Inc.

Completed

A Single-Center, Phase 2 Study Evaluating Bilastine Ophthalmic Solution in the CAC® Model

Allergic Conjunctivitis

United States
R-Pharm
Covance; Cromos Pharma LLC

Withdrawn

Study of the Efficacy and Safety of a Single Administration of Olokizumab vs. Placebo in Addition to Standard Treatment in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19).

COVID-19
ORA, Inc.

Completed

Study Evaluating the Efficacy and Safety of PRT-2761 for the Treatment of Acute and Chronic Allergic Conjunctivitis

Allergic Conjunctivitis

United States
ORA, Inc.

Unknown

Visual Function Tests in Age-related Macular Degeneration

Age Related Macular Degeneration

United States
ORA, Inc.

Completed

Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model

Allergic Conjunctivitis

United States
ORA, Inc.

Completed

Food Allergy Diagnostic Test Response to Previous Oral Challenge Response

Food Hypersensitivity

United States
ORA, Inc.

Completed

A Single-Center Pilot Study to Assess Macular Function

Macular Degeneration

United States
ORA, Inc.

Completed

A Pilot Study Evaluating the Signs and Symptoms of Seasonal Allergic Rhinoconjunctivitis Following Exposure in the Allergen BioCube

Allergic Rhinoconjunctivitis

United States
ORA, Inc.

Completed

A Single-Center Evaluation of the Pattern of Allergic Signs and Symptoms During 4 Weeks in Ragweed Season

Allergic Conjunctivitis

United States
ORA, Inc.

Terminated

Efficacy Study of Ketorolac and HPMC to Treat Dry Eye

Dry Eye

United States

3

Subscribe